☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Argenx
argenx’ Vyvgart Hytrulo Bags the US FDA’s Approval for Treating Chronic Inflammatory Demyelinating Polyneuropathy
June 25, 2024
argenx Reports the US FDA’s Acceptance of sBLA for Vyvgart Hytrulo with Priority Review for Chronic Inflammatory Demyelinating Pol...
February 20, 2024
argenx’s Vyvdura Injection Receives MHLW’s Approval for Generalized Myasthenia Gravis
January 18, 2024
Insights+: EMA Marketing Authorization of New Drugs in November 2023
December 29, 2023
Argenx Reports Results of VYVGART Hytrulo in P-III study for Primary Immune Thrombocytopenia
November 28, 2023
argenx’s Vyvgart with Halozyme’s Enhanze Receives the EC’s Approval for the Treatment of Generalized Myasthenia Gravis
November 17, 2023
Load more...
Back to Home
Modal title
×
Modal body text goes here.